首页> 外文期刊>Managerial finance >Capital structure, competitive intensity and firm performance: an analysis of Indian pharmaceutical companies
【24h】

Capital structure, competitive intensity and firm performance: an analysis of Indian pharmaceutical companies

机译:资本结构,竞争强度和公司性能:印度制药公司的分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose - This research paper aims to explore the relationship of financial performance and capital structure of Indian pharma firms of BSE 500, the impact of research and development (R&D) expenditure on financial performance and also explore the moderating role of competitive intensity between the existing relationship of capital structure and firm performance. Design/methodology/approach - The balanced panel data of listed pharma firms of BSE 500 are used for the research study, and the present study adopts both the panel and ordinary least square (OLS) estimation techniques to draw the results. Findings - The results exhibit that the high debt ratio is harmful for the accounting performance of the selected sample of pharma firms of BSE 500. Besides, market competition negatively moderates the relationship between capital structure and firm performance. Research limitations/implications - The research findings provide evidence for the policymakers/ regulators that the sample firms should discourage the high debt financing in the presence of competitive intensity in the product marketplace. Originality/value - The core contribution of the current research is to examine impact of R&D expenditure on financial performance and the moderating role of market competition on the relationship of capital structure and firm performance to the best of the authors' knowledge, and no single study has previously explored this relationship in the context of BSE 500 pharma firms.
机译:目的 - 本研究论文旨在探讨印度500强的印度制药公司的金融业绩和资本结构的关系,研究和开发(研发)支出对财务绩效的影响,并探讨了现有关系之间竞争力的调节作用资本结构与企业绩效。设计/方法/方法 - BSE 500的上市制药公司的平衡面板数据用于研究研究,本研究采用面板和普通最小二乘(OLS)估计技术来吸取结果。调查结果 - 结果表明,高债务比例对BSE 500的选定样本的会计绩效有害。此外,市场竞争对资本结构与公司绩效之间的关系进行了脱力。研究限制/含义 - 研究结果为决策者/监管机构提供了样本公司在产品市场竞争强度存在下劝阻高债务融资的证据。原创性/价值 - 目前研究的核心贡献是检查研发支出对金融业绩的影响以及市场竞争对资本结构与公司知识的最佳关系的调节作用,没有单一研究以前在BSE 500 Pharma公司的背景下探讨了这种关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号